GlassScriptPhysician profile
Marc S Coan
NPI 1174516330
$10,360.04
in general payments reported to CMS, 2019-2025
47 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $1,356 · 2021: $1,688 · 2022: $1,826 · 2023: $1,771 · 2024: $1,194 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,469.61 | 2019-2025 | |
| Amgen INC. | $1,347.67 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $977.36 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $934.14 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.60 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $734.49 | 2021-2025 | |
| Novo Nordisk INC | $557.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $536.12 | 2019-2023 | |
| Lilly USA, LLC | $399.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $263.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $234.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $167.18 | 2019-2024 | Trelegy Ellipta, Menveo, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.58 | 2019-2024 | Xifaxan |
| Corcept Therapeutics | $137.28 | 2019-2024 | Korlym |
| Astellas Pharma US INC | $125.14 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Coan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.